{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00621452",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2154.00"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "NCI-2010-00416",
            "SecondaryIdType": "Registry Identifier",
            "SecondaryIdDomain": "CTRP (Clinical Trial Reporting Program)"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Fred Hutchinson Cancer Research Center",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
      "OfficialTitle": "A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2014",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 2007"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 21, 2008",
      "StudyFirstSubmitQCDate": "February 21, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 22, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "August 4, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 6, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Fred Hutchinson Cancer Research Center",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Cancer Institute (NCI)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This phase I trial is studying the side effects of giving genetically engineered lymphocytes together with cyclophosphamide and aldesleukin in treating patients with relapsed or refractory mantle cell lymphoma or indolent B-cell non-Hodgkin lymphoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Aldesleukin may stimulate the white blood cells to kill lymphoma cells. Giving genetically engineered lymphocytes together with cyclophosphamide and aldesleukin may be an effective treatment for mantle cell lymphoma and B-cell non-Hodgkin lymphoma",
      "DetailedDescription": "PRIMARY OBJECTIVES:\n\nI. To assess the feasibility, safety and toxicity of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a \"second generation' cluster of differentiation (CD)20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor in patients with recurrent or refractory CD20+ mantle cell or indolent lymphoma.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the duration of in vivo persistence of adoptively transferred CD20-specific T cells transfected with a CD20-specific scFvFc:CD28:CD137:zeda chimeric immunoreceptor.\n\nII. To assess the trafficking of CD20-specific T cells to lymphoma masses. III. To evaluate the development of host anti-CD20 scFvFc:CD28:CD137:zeda chimeric immunoreceptor and anti-neomycin-resistance gene (NeoR) immune responses in study subjects.\n\nOUTLINE:\n\nCHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.\n\nIMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.\n\nMAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.\n\nTreatment continues in the absence of disease progression or unacceptable toxicity.\n\nSubjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse.\n\nAfter completion of study treatment, patients are followed up weekly for one month, monthly for 1 year, and then annually for up to 2 years."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "B-cell Chronic Lymphocytic Leukemia",
          "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
          "Nodal Marginal Zone B-cell Lymphoma",
          "Recurrent Grade 1 Follicular Lymphoma",
          "Recurrent Grade 2 Follicular Lymphoma",
          "Recurrent Mantle Cell Lymphoma",
          "Recurrent Marginal Zone Lymphoma",
          "Recurrent Small Lymphocytic Lymphoma",
          "Refractory Chronic Lymphocytic Leukemia",
          "Splenic Marginal Zone Lymphoma",
          "Waldenstr√∂m Macroglobulinemia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "12",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment (autologous CD20 specific T-cells)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.\n\nIMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.\n\nMAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.\n\nSubjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: therapeutic autologous lymphocytes",
                "Drug: cyclophosphamide",
                "Biological: aldesleukin",
                "Genetic: polymerase chain reaction",
                "Genetic: gene rearrangement analysis",
                "Procedure: lymph node biopsy",
                "Biological: genetically engineered lymphocyte therapy",
                "Procedure: bone marrow aspiration",
                "Other: flow cytometry",
                "Other: laboratory biomarker analysis",
                "Other: enzyme-linked immunosorbent assay"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "therapeutic autologous lymphocytes",
            "InterventionDescription": "Given IV",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "AL",
                "Autologous Lymphocytes",
                "autologous T cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "cyclophosphamide",
            "InterventionDescription": "Given IV",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "CPM",
                "CTX",
                "Cytoxan",
                "Endoxan",
                "Endoxana"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "aldesleukin",
            "InterventionDescription": "Given subcutaneously",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "IL-2",
                "Proleukin",
                "recombinant human interleukin-2",
                "recombinant interleukin-2"
              ]
            }
          },
          {
            "InterventionType": "Genetic",
            "InterventionName": "polymerase chain reaction",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "PCR"
              ]
            }
          },
          {
            "InterventionType": "Genetic",
            "InterventionName": "gene rearrangement analysis",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "lymph node biopsy",
            "InterventionDescription": "Optional correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Biopsy of Lymph Node"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "genetically engineered lymphocyte therapy",
            "InterventionDescription": "Receive genetically modified T cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "bone marrow aspiration",
            "InterventionDescription": "Optional correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "flow cytometry",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "laboratory biomarker analysis",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "enzyme-linked immunosorbent assay",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (autologous CD20 specific T-cells)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "ELISA"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0",
            "PrimaryOutcomeDescription": "A true grade 3 or higher toxicity rate in excess of 20% attributed to T cell infusions will be considered grounds for stopping the study and amending the protocol to lower the cell infusion doses. If there ever exists sufficient evidence to suggest that the true T cell-related toxicity rate (grade 3 or higher, with the exception of fever > 40 degrees Celsius lasting less than 24 hours) exceeds 20%, the study will be stopped.",
            "PrimaryOutcomeTimeFrame": "Up to 2 years after final T cell infusion"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion",
            "SecondaryOutcomeDescription": "Numbers and percentages of CD20-specific T cells and of malignant B cells will also be quantified in lymph node (LN) and bone marrow (BM).",
            "SecondaryOutcomeTimeFrame": "Up to 4 weeks after the third infusion"
          },
          {
            "SecondaryOutcomeMeasure": "Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays",
            "SecondaryOutcomeDescription": "Means, medians and standard deviation (S.D.) of the Ab titers observed will be computed.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months following treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood",
            "SecondaryOutcomeTimeFrame": "Up to 1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale or female subjects with immuno histopathologically documented CD20+ mantle cell lymphoma, follicular non-Hodgkin lymphoma (NHL), small lymphocytic lymphoma/chronic lymphocytic leukemia, marginal zone, or lymphoplasmacytic NHL of any age, gender, or ethnic group who have relapsed or are refractory to conventional chemotherapy and who are not eligible for Fred Hutchinson Cancer Research Center (FHCRC)/University of Washington Medical Center (UWMC) transplant protocols (or who refuse participation in transplant protocols)\nWillingness to sign an informed consent and undergo study tests\nWillingness to receive cytoreductive chemotherapy, if necessary to debulk tumors prior to T cell administration, and to receive cyclophosphamide for lymphodepletion\nSerologic evidence of prior exposure to Epstein-Barr virus (EBV)\nMeets safety criteria to undergo leukapheresis\nHemoglobin > 9.0 gm/dL\nWhite blood cell (WBC) > 2500 per microliter\nAlanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x Upper Limit of Normal\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x Upper Limit of Normal\nCreatinine =< 1.6 mg/dL\nWillingness to use acceptable (barrier or hormonal methods) birth control as appropriate during the course of the study\n\nExclusion Criteria:\n\nTreatment with fludarabine or cladribine within the previous 2 years prior to apheresis\nKnown central nervous system involvement with NHL\nPulmonary involvement with NHL; a diagnosis of pulmonary lymphoma will be based in part on findings from chest computed tomography (CT) and, if clinically appropriate, lung biopsy\nExposure to chemotherapeutic agents (standard or experimental) or other immunosuppressive therapies less than four weeks prior to apheresis; patients must have recovered from acute side effects of such therapy\nPositive serology for human immunodeficiency virus (HIV)\nActive Hepatitis B or Hepatitis C infection\nHistory of hypersensitivity reactions to murine proteins or seropositivity for human anti-mouse antibody (HAMA)\nRequirement for corticosteroid therapy during the study period unless used specifically for amelioration of toxicity induced by transferred cells\nTreatment with anti-CD20 antibodies (rituximab, tositumomab, ibritumomab) within 4 months prior to start of T cell infusions\nPatients with lymph nodes in excess of 5 cm in diameter at time of T cell infusion\nPatients with > 5000 circulating CD20+ lymphocytes per mm^3 at time of T cell infusion\nPrevious allogeneic stem cell transplantation\nLife expectancy less than 90 days\nPregnancy",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Brian Till",
            "OverallOfficialAffiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium",
            "LocationCity": "Seattle",
            "LocationState": "Washington",
            "LocationZip": "98109",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "22308288",
            "ReferenceType": "derived",
            "ReferenceCitation": "Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008223",
            "ConditionMeshTerm": "Lymphoma"
          },
          {
            "ConditionMeshId": "D000007938",
            "ConditionMeshTerm": "Leukemia"
          },
          {
            "ConditionMeshId": "D000008224",
            "ConditionMeshTerm": "Lymphoma, Follicular"
          },
          {
            "ConditionMeshId": "D000007945",
            "ConditionMeshTerm": "Leukemia, Lymphoid"
          },
          {
            "ConditionMeshId": "D000015451",
            "ConditionMeshTerm": "Leukemia, Lymphocytic, Chronic, B-Cell"
          },
          {
            "ConditionMeshId": "D000016393",
            "ConditionMeshTerm": "Lymphoma, B-Cell"
          },
          {
            "ConditionMeshId": "D000020522",
            "ConditionMeshTerm": "Lymphoma, Mantle-Cell"
          },
          {
            "ConditionMeshId": "D000018442",
            "ConditionMeshTerm": "Lymphoma, B-Cell, Marginal Zone"
          },
          {
            "ConditionMeshId": "D000008258",
            "ConditionMeshTerm": "Waldenstrom Macroglobulinemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000008228",
            "ConditionAncestorTerm": "Lymphoma, Non-Hodgkin"
          },
          {
            "ConditionAncestorId": "D000015448",
            "ConditionAncestorTerm": "Leukemia, B-Cell"
          },
          {
            "ConditionAncestorId": "D000054219",
            "ConditionAncestorTerm": "Neoplasms, Plasma Cell"
          },
          {
            "ConditionAncestorId": "D000020141",
            "ConditionAncestorTerm": "Hemostatic Disorders"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000010265",
            "ConditionAncestorTerm": "Paraproteinemias"
          },
          {
            "ConditionAncestorId": "D000001796",
            "ConditionAncestorTerm": "Blood Protein Disorders"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000006474",
            "ConditionAncestorTerm": "Hemorrhagic Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17980",
            "ConditionBrowseLeafName": "Lymphoma, B-Cell",
            "ConditionBrowseLeafAsFound": "B-cell Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafAsFound": "Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10103",
            "ConditionBrowseLeafName": "Leukemia, Lymphoid",
            "ConditionBrowseLeafAsFound": "Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17268",
            "ConditionBrowseLeafName": "Leukemia, Lymphocytic, Chronic, B-Cell",
            "ConditionBrowseLeafAsFound": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10403",
            "ConditionBrowseLeafName": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafAsFound": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10373",
            "ConditionBrowseLeafName": "Lymphoma, Follicular",
            "ConditionBrowseLeafAsFound": "Follicular lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21460",
            "ConditionBrowseLeafName": "Lymphoma, Mantle-Cell",
            "ConditionBrowseLeafAsFound": "Mantle cell lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19707",
            "ConditionBrowseLeafName": "Lymphoma, B-Cell, Marginal Zone",
            "ConditionBrowseLeafAsFound": "Marginal zone B-cell lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10374",
            "ConditionBrowseLeafName": "Lymphoma, Non-Hodgkin",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17267",
            "ConditionBrowseLeafName": "Leukemia, B-Cell",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M26741",
            "ConditionBrowseLeafName": "Neoplasms, Plasma Cell",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21130",
            "ConditionBrowseLeafName": "Hemostatic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4211",
            "ConditionBrowseLeafName": "Blood Coagulation Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12330",
            "ConditionBrowseLeafName": "Paraproteinemias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4229",
            "ConditionBrowseLeafName": "Blood Protein Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8712",
            "ConditionBrowseLeafName": "Hemorrhagic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T640",
            "ConditionBrowseLeafName": "B-cell Lymphoma",
            "ConditionBrowseLeafAsFound": "B-cell Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1308",
            "ConditionBrowseLeafName": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafAsFound": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T5887",
            "ConditionBrowseLeafName": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafAsFound": "Waldenstrom Macroglobulinemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2361",
            "ConditionBrowseLeafName": "Follicular Lymphoma",
            "ConditionBrowseLeafAsFound": "Follicular lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3601",
            "ConditionBrowseLeafName": "Mantle Cell Lymphoma",
            "ConditionBrowseLeafAsFound": "Mantle cell lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3612",
            "ConditionBrowseLeafName": "Marginal Zone Lymphoma",
            "ConditionBrowseLeafAsFound": "Marginal zone lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3043",
            "ConditionBrowseLeafName": "Indolent B Cell Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000082598",
            "InterventionMeshTerm": "Aldesleukin"
          },
          {
            "InterventionMeshId": "D000003520",
            "InterventionMeshTerm": "Cyclophosphamide"
          },
          {
            "InterventionMeshId": "D000007376",
            "InterventionMeshTerm": "Interleukin-2"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000018906",
            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
          },
          {
            "InterventionAncestorId": "D000000477",
            "InterventionAncestorTerm": "Alkylating Agents"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000019653",
            "InterventionAncestorTerm": "Myeloablative Agonists"
          },
          {
            "InterventionAncestorId": "D000018712",
            "InterventionAncestorTerm": "Analgesics, Non-Narcotic"
          },
          {
            "InterventionAncestorId": "D000000700",
            "InterventionAncestorTerm": "Analgesics"
          },
          {
            "InterventionAncestorId": "D000018689",
            "InterventionAncestorTerm": "Sensory System Agents"
          },
          {
            "InterventionAncestorId": "D000018373",
            "InterventionAncestorTerm": "Peripheral Nervous System Agents"
          },
          {
            "InterventionAncestorId": "D000019380",
            "InterventionAncestorTerm": "Anti-HIV Agents"
          },
          {
            "InterventionAncestorId": "D000044966",
            "InterventionAncestorTerm": "Anti-Retroviral Agents"
          },
          {
            "InterventionAncestorId": "D000000998",
            "InterventionAncestorTerm": "Antiviral Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafAsFound": "Months",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M225462",
            "InterventionBrowseLeafName": "Aldesleukin",
            "InterventionBrowseLeafAsFound": "Molecular",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M9563",
            "InterventionBrowseLeafName": "Interleukin-2",
            "InterventionBrowseLeafAsFound": "Evaluated",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20095",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2972",
            "InterventionBrowseLeafName": "Alkylating Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3184",
            "InterventionBrowseLeafName": "Analgesics",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19939",
            "InterventionBrowseLeafName": "Analgesics, Non-Narcotic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20503",
            "InterventionBrowseLeafName": "Anti-HIV Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M24581",
            "InterventionBrowseLeafName": "Anti-Retroviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3466",
            "InterventionBrowseLeafName": "Antiviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Analg",
            "InterventionBrowseBranchName": "Analgesics"
          }
        ]
      }
    }
  }
}